These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19380447)

  • 41. Effect of darbepoetin alfa on exercise tolerance in anemic patients with symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled trial.
    Ponikowski P; Anker SD; Szachniewicz J; Okonko D; Ledwidge M; Zymlinski R; Ryan E; Wasserman SM; Baker N; Rosser D; Rosen SD; Poole-Wilson PA; Banasiak W; Coats AJ; McDonald K
    J Am Coll Cardiol; 2007 Feb; 49(7):753-62. PubMed ID: 17306703
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study.
    Tsuboi M; Ezaki K; Tobinai K; Ohashi Y; Saijo N
    Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.
    Bohlius J; Schmidlin K; Brillant C; Schwarzer G; Trelle S; Seidenfeld J; Zwahlen M; Clarke MJ; Weingart O; Kluge S; Piper M; Napoli M; Rades D; Steensma D; Djulbegovic B; Fey MF; Ray-Coquard I; Moebus V; Thomas G; Untch M; Schumacher M; Egger M; Engert A
    Cochrane Database Syst Rev; 2009 Jul; 2009(3):CD007303. PubMed ID: 19588423
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Recombinant human erythropoietin in cancer-related anemia. Review of clinical evidence.
    Crawford J
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):41-53. PubMed ID: 12380954
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Continuing reassessment of the risks of erythropoiesis-stimulating agents in patients with cancer.
    Juneja V; Keegan P; Gootenberg JE; Rothmann MD; Shen YL; Lee KY; Weiss KD; Pazdur R
    Clin Cancer Res; 2008 Jun; 14(11):3242-7. PubMed ID: 18519748
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical benefits and risks associated with epoetin and darbepoetin in patients with chemotherapy-induced anemia: a systematic review of the literature.
    Ross SD; Allen IE; Henry DH; Seaman C; Sercus B; Goodnough LT
    Clin Ther; 2006 Jun; 28(6):801-31. PubMed ID: 16860166
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of darbepoetin alfa initiated at hemoglobin ≤10 g/dL in patients with stage IV cancer and chemotherapy-induced anemia.
    Boccia RV; Henry DH; Belton L; Bohac C; Ghazal HH
    Cancer Med; 2016 Dec; 5(12):3445-3453. PubMed ID: 27882724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Update on erythropoiesis-stimulating agents and clinical trials in oncology.
    Aapro M; Spivak JL
    Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Darbepoetin alfa 300 or 500 μg once every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia.
    Auerbach M; Silberstein PT; Webb RT; Averyanova S; Ciuleanu TE; Shao J; Bridges K
    Am J Hematol; 2010 Sep; 85(9):655-63. PubMed ID: 20661916
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The blue cross blue shield assessment technology review: summary of findings.
    Bennett CL
    Best Pract Res Clin Haematol; 2005; 18(3):423-31. PubMed ID: 15792916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of latent growth curve models for assessing the effects of darbepoetin alfa on hemoglobin and fatigue.
    Stull DE; Vernon MK; Legg JC; Viswanathan HN; Fairclough D; Revicki DA
    Contemp Clin Trials; 2010 Mar; 31(2):172-9. PubMed ID: 20060499
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Erythropoietin or darbepoetin for patients with cancer.
    Tonia T; Mettler A; Robert N; Schwarzer G; Seidenfeld J; Weingart O; Hyde C; Engert A; Bohlius J
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003407. PubMed ID: 23235597
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Darbepoetin alfa effectively maintains haemoglobin concentrations at extended dose intervals relative to intravenous or subcutaneous recombinant human erythropoietin in dialysis patients.
    Brunkhorst R; Bommer J; Braun J; Haag-Weber M; Gill C; Wagner J; Wagener T;
    Nephrol Dial Transplant; 2004 May; 19(5):1224-30. PubMed ID: 14993489
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Assessment of hematologic effects and fatigue in cancer patients with chemotherapy-induced anemia given darbepoetin alfa every two weeks.
    Vadhan-Raj S; Mirtsching B; Charu V; Terry D; Rossi G; Tomita D; McGuire WP
    J Support Oncol; 2003; 1(2):131-8. PubMed ID: 15352656
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of darbepoetin alfa and epoetin alfa in the management of anemia of critical illness.
    Voils SA; Harpe SH; Brophy GM
    Pharmacotherapy; 2007 Apr; 27(4):535-41. PubMed ID: 17381380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Meta-analysis of epoetin beta and darbepoetin alfa treatment for chemotherapy-induced anemia and mortality: Individual patient data from Japanese randomized, placebo-controlled trials.
    Ohashi Y; Uemura Y; Fujisaka Y; Sugiyama T; Ohmatsu H; Katsumata N; Okamoto R; Saijo N; Hotta T
    Cancer Sci; 2013 Apr; 104(4):481-5. PubMed ID: 23331490
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Erythropoiesis-stimulating protein support and survival.
    Crawford J
    Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):39-43. PubMed ID: 16925111
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A Randomized, Double-Blind, Placebo-Controlled, Phase III Noninferiority Study of the Long-Term Safety and Efficacy of Darbepoetin Alfa for Chemotherapy-Induced Anemia in Patients With Advanced NSCLC.
    Gascón P; Nagarkar R; Šmakal M; Syrigos KN; Barrios CH; Sánchez JC; Zhang L; Henry DH; Gordon D; Hirsh V; Kubota K; Orlov S; Thomas G; Steinmetz T; Kang JH; Tomita DK; Fleishman AN; Park JK; De Oliveira Brandao C
    J Thorac Oncol; 2020 Feb; 15(2):190-202. PubMed ID: 31629060
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anemia in cancer patients: significance, epidemiology, and current therapy.
    Tchekmedyian NS
    Oncology (Williston Park); 2002 Sep; 16(9 Suppl 10):17-24. PubMed ID: 12380951
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimizing the treatment of anemia in cancer patients. The role of a new erythropoietic agent.
    Henry DH
    Oncology (Williston Park); 2002 Oct; 16(10 Suppl 11):9-12. PubMed ID: 12435168
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.